Megan Kruse, MD

Patient Education, Shared Decision-Making, and Optimizing Care for ESR1-Mutated Breast Cancer

May 15, 2025

Video

Panelists discuss how a multidisciplinary team approach to patient education and medication management is crucial for ensuring adherence and optimal outcomes with oral medications like elacestrant

Real-World Experience: The Efficacy and Tolerability of Oral Elacestrant for Patients with ESR1 Mutations

May 15, 2025

Video

Panelists discuss how real-world studies have shown improved outcomes with elacestrant compared with the original EMERALD trial data, demonstrating that proper patient selection leads to better treatment responses.

Managing Elacestrant Treatment: From Patient Selection to Supportive Care

May 08, 2025

Video

Panelists discuss balancing clinical trial data with real-world patient factors when choosing between treatment options, emphasizing the importance of quality of life alongside cancer control in the second-line setting.

EMERALD Trial Results: What Prior CDK4/6i Duration Means for Treatment Success

May 08, 2025

Video

Panelists discuss how the EMERALD trial demonstrated elacestrant's efficacy in ESR1-mutated tumors, particularly in patients who had received CDK4/6 inhibitors for at least 12 months. This led to its FDA approval for this specific population.